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Introduction 
Migrants to the UK from countries, such as Pakistan, with high prevalence rates of hepatitis 
C virus (HCV) may be more likely to be infected than the general UK population[1-2]. Those 
who are infected often acquire the virus in childhood and will carry the infection 
asymptomatically for many years, only being diagnosed when they show symptoms 
associated with advanced liver disease[3]. In the UK, those of South Asian origin are 
significantly more likely (up to nine times higher for those of Pakistani ethnicity) to be 
admitted to hospital with HCV-related end-stage liver disease, and die from this indication, 
than the Caucasian population[2].   
 
To inform the development of targeted HCV testing and treatment services among South 
Asians, we first need to determine the prevalence of HCV infection among those living in the 
country. However, obtaining an accurate population-based prevalence estimate can be 
difficult. HCV surveillance data are confined to those who have presented for a diagnostic 
test either because they are symptomatic or they, or their clinician, perceive themselves to 
be at risk; thus the prevalence of infection among those who have been tested for HCV will 
tend to be higher than that in the overall population. Furthermore population-based surveys 
may be hampered by challenges associated with accessing the population and with getting 
them to engage with scientific research[4].  Uddin et al., the authors of the only previous 
HCV prevalence survey conducted among South Asians living in the UK (specifically 
England)[5], considered a range of recruitment methods but ultimately employed a named 
testing approach within community and religious centres to generate a representative 
sample.  
 
In Scotland, 1% of the five million population defines themselves as being of South Asian 
origin, with 60% being of Pakistani ethnicity, making them the largest minority ethnic group 
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in the country[6]. No surveys have previously been conducted to determine their prevalence 
of HCV; consequently the burden of disease in this population is unknown.  
 
We examined HCV prevalence data, in the Greater Glasgow and Clyde (GGC) Health Board 
area where over half of Scotland’s South Asian population resides, from two sources: (i) a 
community-based survey and case finding initiative (hereafter known as the community 
based survey) similar to the screening study undertaken by Uddin et al.[5] and (ii) HCV 
laboratory surveillance data. Through examination and synthesis of HCV prevalence data 
from these two sources (a community-based sample of predominantly individuals who had 
never been tested for HCV and surveillance data on all individuals who had ever been tested 
for HCV), we aimed to estimate the prevalence of HCV among those of South Asian origin, 
and to determine the extent of diagnosed/undiagnosed HCV infection in this population. In 
addition, using the community-based survey data, we compared the prevalence of HCV 
among first and second generation migrants of South Asian origin and identified risk-factors 
for infection in this population.  
 
In addition, given the reported higher prevalence rates of hepatitis B virus (HBV) among 
South Asian migrants compared to the general population in the UK[7-9], we estimated the 
prevalence of HBV infection among participants in the community-based survey.  
 
These data will inform whether case finding in the South Asian population, or its subgroups, 
is warranted.  
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Materials and Methods  
 
Community-based survey 
Participants were recruited from six mosques and four community centres serving the South 
Asian community in the GGC area between December 2009 and August 2010. Selection of 
mosques and community centres was based on their ability to accommodate testing on or 
close to their premises. All persons aged 18 years or older attending Friday prayers at the 
mosques and attending the community centres on survey days were invited to participate. 
Posters and announcements in the local media serving the South Asian community were 
used to disseminate information about the survey and testing sessions to our target 
population. Announcements were also made in the mosques in the run-up to survey days, 
and those attending mosques were invited to inform family members and other household 
contacts about the survey and that they could also participate and be tested.  
 
Individuals were given the option to participate and be tested for both HCV and HBV 
infection on either a named or anonymous basis. Thus, individuals who did not wish to 
receive their test results for any reason (e.g. they had previously been tested) were 
encouraged to participate and get tested in an anonymous manner, in order to minimise 
potential bias generated by a self-selected group coming forward for named testing. 
Informed written consent was obtained from all participants by trained Urdu speaking 
fieldworkers, who also collected demographic and risk factor data for each participant using 
a standardised questionnaire. Nurses were employed to take dried blood spot (DBS) samples 
from participants. Those who participated on a named basis were notified of the result of 
their HCV and HBV test, and, where appropriate, were invited to attend a local specialist 
centre for confirmatory blood testing and further management and treatment. We obtained 
ethical approval for this study from the Glasgow West Research Ethics Committee. 
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DBS samples were tested for HCV and HBV at the West of Scotland Specialist Virology 
Centre. Samples were eluted and tested for HCV antibody using a modified protocol for the 
Ortho HCV 3.0 SAVe ELISA (product number 940982, Ortho Diagnostics, Amersham)[10]. This 
assay has a sensitivity of 100% (95% CI: 98-100%) and a specificity of 100% (95% CI: 99-
100%) in low prevalence populations[10]. All reactive samples were repeat tested using the 
same assay, and those confirmed were tested for HCV RNA using PCR. DBS samples were 
tested for HBV core antibodies (anti-HBc) and HBV surface antigen (HBsAg) using the Abbott 
Architect automated platform. Confirmatory HCV and HBV tests on follow-up blood samples 
(for those found to be HCV antibody positive and those HBsAg positive on DBS) were 
undertaken according to routine laboratory procedures. 
 
Laboratory surveillance data  
The West of Scotland Specialist Virology Centre provides data to Health Protection Scotland 
(HPS) on all HCV antibody tests performed in the GGC Health Board area for surveillance 
purposes; data for the period 1st January 1993 to 31st December 2009 were available for this 
analysis. Data provided to HPS includes patient identifiers (forename and surname, date of 
birth, gender and a hospital/clinic number or community health index (CHI) number (a 
unique identifier issued in Scotland to all those registered with the National Health Service), 
information on source of referral (here categorised as general practitioner (GP), hospital, 
routine screen or other) and test information (specimen date and HCV antibody result).  
 
The computer programme Nam Pehchan[11] was applied to the names (surnames and 
forenames) recorded on the HCV test database, using a process described in detail 
elsewhere[12], to identify those of South Asian ethnic origin. This approach, reported to 
have a sensitivity in excess of 90%[12], has been previously applied to HCV laboratory 
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surveillance data in England and Wales[13]. Using the names of those who participated in 
the community-based survey (above) as corroboration, we established that the software 
appropriately assigned a high proportion (96%) of respondents as South Asian. 
 
Once the Nam Pehchan software was applied to the HCV test records, full names were 
removed and forename initial and soundex of surname (a consonant-only phonetic 
encoding[14]) were retained, prior to analysis. Repeat or subsequent HCV test records for an 
individual were identified – on the basis of a match on either (i) sex, date of birth, forename 
initial and surname soundex, (ii) sex, date of birth and hospital/clinic number, or (iii) CHI 
number – and removed from further analysis.  
 
Data Analysis 
First, we examined the proportion who tested HCV antibody positive (i.e. prevalence of 
infection) in the two study populations:  1) individuals of South Asian origin who were tested 
for HCV antibodies in the community-based survey and in GGC during 2009-2010, and 2) 
individuals who had had a diagnostic HCV antibody test in GGC during 1993-2009 and who 
were assigned as South Asian according to Nam Pechan. For each population, we generated 
the prevalence of infection (and 95% confidence interval (CI)) for all those tested for HCV 
antibodies, and stratified according to demographic characteristics and risk factors. Further, 
we conducted univariable and multivariable logistic regression analyses to determine the 
factors significantly associated with the prevalence of HCV infection in these two study 
populations. We analysed data using R[15]. 
 
We then generated an estimate of the overall prevalence of HCV infection among South 
Asians living in GGC during 2009, by combining information on:  
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a) the size of the South Asian population living in GGC in 2009, stratified according 
to (i) those who had been previously tested for HCV infection, (ii) those who had 
not previously been tested for HCV and were born outside the UK, and (iii) those 
who had not previously been tested for HCV and were born in the UK; and 
b) the prevalence of HCV infection in these South Asian sub-populations (i)-(iii).  
 
For a), the size of the South Asian population living in GGC aged ≥18 years was estimated 
based on the number of individuals of Asian/Asian British ethnicity (excluding Chinese) living 
in Scotland for 2009 (N=82,500) as reported in the Annual Population Survey[16], adjusted 
for the proportion of South Asians residing in GGC (53%) and aged ≥18 years (65%) based on 
the Scottish 2001 Census[6]. This estimated population was then stratified according to 
those who had ever/never been tested for HCV, based on the number of individuals who 
had ever been tested for HCV in GGC during 1993-2009 from the HCV laboratory surveillance 
data, and who were not known to have died before 2009 (7%) according to linked mortality 
data.  The estimated population of South Asians who had never been tested for HCV was 
further stratified according to those born in and outside the UK, based on the Scottish 2001 
Census[6].  
 
For b), the prevalence of HCV in the South Asian sub-populations was derived based on the 
laboratory HCV surveillance data for those who had ever been tested for HCV (and were not 
known to have died from the linked mortality data), and the community-based survey data 
for those who had never been tested for HCV and were either born in or outside the UK. Due 
to the relatively small number of UK-born South Asians who were recruited to the 
community-based survey in GGC, we generated an estimate of the prevalence of HCV among 
this sub-population by combining data from the survey conducted in GGC (where one out of 
168 UK-born South Asians was found to be HCV infected, see Table 1) with that from a larger 
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community-based survey undertaken in England[5] (where two out of 452 UK-born South 
Asians were found to be HCV infected). 
 
 Page 12  
Results  
Community-based survey  
Characteristics of participants 
A total of 1,288 individuals participated, completed a questionnaire and provided a DBS 
sample for HCV and HBV testing; all participants requested to have their test results 
returned to them, and thus no-one took part anonymously. Almost two-thirds (833/1288) of 
participants were recruited from mosques and the rest from community centres. Based on 
estimates of the total number of people attending recruitment venues on survey days, 
approximately 25% of those attending mosques and 40% of those attending community 
centres participated. All participants were of South Asian origin. 
 
The majority of participants were male (63%), aged 30-69 years (69%) and born outside the 
UK (87%; with 79% of these born in Pakistan) (Table 1). Fourteen percent of participants 
reported that a family member was infected with HCV. Eleven percent of participants had 
had surgery in South Asia, and a further 36% reported having had either medical/dental 
treatment or an injection in South Asia.  
 
Ten percent (127/1288) of participants reported having previously been tested for HCV; of 
these, 9% (11/127) reported a positive diagnosis (equating to 0.9% of all respondents). Four 
percent (46/1288) of respondents reported a history of liver disease (with 15 reporting viral 
hepatitis, 5 jaundice, 4 liver abscesses, 1 cirrhosis and 21 unknown or unspecified liver 
disease). 
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Prevalence of HCV 
Among all participants, 34 (2.6%, 95% CI: 1.9–3.7) were found to be HCV antibody positive 
on DBS (Table 1), and 62% (21/34) of these were also found to be HCV RNA positive 
(representing 1.6% of all participants). Among the eleven participants who reported that 
they had been previously diagnosed with HCV, ten (91%) tested HCV antibody positive on 
DBS. Thus, 71% (24/34) of HCV antibody positive cases detected in the survey/case-finding 
initiative were among individuals who were previously undiagnosed. The prevalence of HCV 
antibodies ranged from 0.6% (1/168) among those born in the UK to 3.1% (27/882) among 
those born in Pakistan (p=0.07). 
 
The odds of testing HCV antibody positive were significantly raised among participants aged 
30 to 49 years compared with those aged 18 to 29 years (adjusted odds ratio (aOR) 4.1; 95% 
CI: 1.0–17.2), and participants reporting having received surgery in South Asia (5.0; 95% CI: 
2.0–12.3) and either medical/dental treatment or an injection in South Asia (2.2; 95% CI: 
1.0–5.0) compared with those who had not reported receiving any of these treatments in 
South Asia (Table 1). 
 
Prevalence of HBV 
Among all participants, 44 (3.4%, 95% CI: 2.6–4.6) were found to be anti-HBc positive on 
DBS. Of these, 27% (12/44) were also found to be HBsAg reactive (representing 0.9% of all 
participants), and none tested HBV IgM antibody positive. HBsAg reactivity was not 
significantly associated with age, sex, country of birth or with medical-related treatments 
received in South Asia (data available from authors on request). One individual was co-
infected with both HBV and HCV, testing both anti-HBc, HBsAg reactive and HCV antibody 
and HCV RNA positive. 
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Follow-up of cases 
Of the 21 participants found to be HCV RNA positive on DBS, 19 (90%) attended a specialist 
centre for confirmatory blood testing; the majority of these (14/17: 82%) were infected with 
HCV genotype 3. Of the nineteen patients who attended a specialist centre, 15 (79%) 
continued to attend for follow-up treatment and care; of the remaining four patients, three 
returned to Pakistan and one person died during follow-up. Of those who attended for 
follow-up treatment and care, eight (53%) were initiated on HCV antiviral therapy within 18 
months of their diagnosis. Of the seven who were not yet initiated on therapy, one had 
previously been treated and two had contraindications.  
 
Of the twelve participants found to be HBsAg positive on DBS, seven (58%) attended a 
specialist centre for confirmatory blood tests. Of these, five (71%) attended for follow-up 
treatment and care and one was subsequently initiated on HBV antiviral therapy within 18 
months of diagnosis.   
 
Laboratory surveillance data  
Among individuals tested for HCV antibodies in the GGC area during 1993-2009, 6404 were 
assigned as being of South Asian origin using the Nam Pechan software. The majority of 
these individuals had been first tested for HCV antibodies during 2005-2009 (56%) and a 
large proportion had been tested by a GP (44%) (Table 2). Among those who had been 
tested for HCV antibodies during 1993-2009 and who were assigned as South Asian, the 
proportion found to be HCV antibody positive (at their first test) was 9.3% (95% CI: 8.6–
10.1); this prevalence of diagnosed infection was similar to that reported among participants 
in the community-based survey who had previously been tested for HCV.  
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The odds of testing HCV antibody positive among South Asians who had undergone a 
diagnostic HCV test were significantly raised among those aged 30 years or more compared 
with those aged 18 to 29 years (aORs for those aged 30-49 years: 1.6, 95% CI: 1.3–2.0; 50-69 
years: 2.4, 95% CI: 1.8–3.1; and 70+ years: 2.3, 95% CI: 1.5–3.5). The odds of testing HCV 
antibody positive were significantly reduced among those who were first tested in 2000-
2009 compared with those who first tested during 1993-2000 (aORs for those first tested in 
2000-2004: 0.7, 95% CI: 0.6–1.0; and 2005-2009: 0.6, 95% CI: 0.5–0.8), and those referred 
for testing from a hospital setting (aOR 0.7, 95% CI: 0.6–0.9) or from a setting performing 
routine screens (such as fertility clinic, occupational health and renal clinic) (aOR 0.1, 95% CI: 
0.1–0.2) compared with those referred by a GP. No difference in HCV antibody positivity was 
found between males and females (Table 2). 
 
Overall prevalence of HCV infection among South Asians  
Based on data from the annual population survey[16] and the 2001 Scottish Census, we 
estimated that there were approximately 28,430 people aged ≥18 years living in the GGC 
area during 2009, who were of South Asian origin (Figure 1). Of these 28,430 South Asian 
people living in GCC, we estimated that approximately (i) 5,900 (21%) had previously been 
tested for HCV (based on the HCV laboratory surveillance data), (ii) 13,910 (49%) had not 
previously been tested for HCV and were born outside the UK (based also on the 2001 
Census[6]), and (iii) 8,320 (29%) had not previously been tested for HCV and were born in 
the UK. For these three sub-populations, the prevalence of HCV was estimated to range 
from 0.5% among those born in the UK, to 2.0% among those born outside the UK (and who 
had not previously been tested for HCV) and 9.3% among those who had previously been 
tested for HCV. Combining these data (on the size of the three South Asian sub-populations 
(i)-(iii) with the prevalence of HCV infection in each group) generated an overall estimate of 
870 HCV infected South Asians aged ≥18 years living in the GGC area during 2009, 
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representing an overall prevalence of 3.1% (Figure 1). Of these 870 estimated HCV infected 
South Asians, 330 (38%) were estimated to have never been tested and diagnosed with HCV 
infection. 
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Discussion 
Given the previously reported increased risk of HCV related liver disease[2] among South 
Asians, obtaining accurate estimates of the prevalence of HCV in this population is important 
to inform on the targeting of case finding activities.  
 
We analysed data from both a community-based HCV survey and laboratory surveillance 
data to gain insights into the prevalence of HCV among the South Asian community in 
Glasgow. Among participants in the community-based sample, we detected an overall HCV 
prevalence rate of 2.6% (95% CI 1.9-3.7%). This is higher than the 1.6% prevalence detected 
among respondents to a similar multicentre survey in England[5], but is similar to the 2.7% 
prevalence rate that they reported among those born in Pakistan.  In the English survey, 
around half of the respondents were born in Pakistan, compared with almost seventy 
percent of respondents in our survey; this may partially explain our higher prevalence 
estimate of HCV. In our community-based sample, the prevalence of HCV among those born 
in Pakistan was 3.1%, but we also detected a higher prevalence of HCV among those born in 
India (2.9%), compared with the estimated 0.2% prevalence among those born in India 
reported by the English study. Those born in Pakistan and India were five times more likely 
to test HCV antibody positive than those born in the UK, among whom we detected a HCV 
prevalence of 0.6%. The 0.6% prevalence estimate in UK born South Asians is similar to that 
reported by the English survey (0.4%).The prevalence of chronic HCV infection among 
respondents to the community-based survey was 2.6%, compared with an estimated i) 0.8% 
among the total Scottish population[17],ii) 0.1% among the Scottish population excluding 
people who inject drugs (Health Protection Scotland)and iii) 0.004% among repeat blood 
donors(Scottish National Blood Transfusion Service). Respondents to the community survey 
were also more likely to have chronic HBV infection (0.9%) than the general UK population 
(0.3-0.4%)[8, 18-19].  
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The acquisition of  HCV in South Asia is linked to the widespread re-use of needles in the 
healthcare setting[3, 20]  and the use of contaminated blood products[21]. Risk behaviours 
for the acquisition of HCV were common among participants in the Glasgow community 
sample, with almost half having received either medical/dental treatment, surgery or an 
injection in South Asia.  Further we found a significantly increased risk of HCV infection (i.e. 
testing HCV antibody positive) among those who reported having received medical/dental 
treatment, surgery or an injection in South Asia, compared with no history of these. Our 
findings are consistent with those from similar studies undertaken in South Asia[3, 22] and 
highlight the need to educate those travelling to South Asia, of the risks associated with 
undertaking medical procedures in the region. 
 
 
Compared to those aged 18 to 29, there was an increased risk of testing HCV antibody 
positive with age for all those identified as being of South Asian origin on the laboratory 
surveillance database. Those referred for testing by their general practitioner were more 
likely to test positive than those referred for testing from hospital or routine sources.  We 
observed a declining risk of testing HCV antibody positive among those who were first tested 
between 2000 and 2004 and 2005 and 2009, compared with those tested before 2000. This 
may reflect an increasing awareness of the risk of HCV in this population and among their 
health care providers over time, resulting in a corresponding increased uptake of testing 
among a wider cross-section of the community. Alternatively there may be a declining risk of 
infection among more recent non-UK born migrants from South Asia to the UK, a hypothesis 
supported by the observed increased risk of testing antibody positive in the older 
population.  
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Neither of our sources of data is likely to be representative of the general South Asian 
population for a variety of reasons. Our community-based sample was conducted in 
mosques and community centres; those attending these venues may not be representative 
of the general South Asian population in Glasgow. Specifically, those born in South Asia may 
be over-represented; as these individuals are at greater risk of HCV infection than UK born 
South Asians.  Furthermore, participation in the community-based survey was on a self-
selected basis and so may have been influenced by the participants own perceived risk of 
infection with HCV. This is supported by the fact that only ten percent of respondents had 
previously been tested for HCV, compared to over a fifth we estimated to have been tested 
in this population. The possible self-exclusion of those who thought they were not at risk 
may have resulted in an over-estimate of HCV prevalence in this population but similarly the 
self-exclusion of those who already knew they were infected would have resulted in an 
underestimate.  
 
Given that those presenting for testing are more likely to do so either because they are 
symptomatic or are perceived to be at risk of infection, the HCV prevalence estimate derived 
from this source is possibly an overestimate of the prevalence in the general population.  
Despite the recognised limitations of the data from the above sources, we can gain some 
insight into the overall prevalence of HCV among South Asians living in Glasgow, by 
combining the data from both sources. In this way we estimate the HCV antibody prevalence 
among South Asians in Glasgow to be around 3%; three times higher than the estimated 
prevalence among the total population in Scotland[17].  A recent systematic review [23], 
reported a HCV prevalence rate of 1 to 1.9% in India and 4.7% in Pakistan. Our derived 
estimate is therefore consistent with what would be expected in a South Asian population 
where the majority are of Pakistani origin, such as that in Glasgow.  
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Among participants in the community-based survey, 90% of those who tested HCV RNA 
positive on DBS subsequently attended specialist services for confirmatory blood tests and 
80% of those who attended for confirmatory testing attended for follow-up treatment and 
care. This contrasts with a reported 50% attendance at follow-up treatment among former 
injecting drug users identified during a recent case-finding initiative undertaken in primary 
care practices in Glasgow[24]. This provides encouraging evidence that targeted testing of 
South Asians, particularly those born outside the UK, is likely to be successful in reducing the 
burden of disease in this community. 
  
Whereas initiatives to case-find and treat those infected with HCV in Scotland have focused 
on high-risk populations, in particular those with a history of injecting drugs, our results 
support recommendations by the UK National Institute for Clinical Excellence[25] to increase 
awareness and testing among those born or brought up in countries and areas with an 
intermediate or high prevalence of hepatitis, such as those born in South Asia. The most 
cost-effective way to do this requires further investigation. In addition, those travelling to 
South Asia should be advised that undergoing medical, dental and surgical treatment or 
receiving injections in the region may increase their risk of contracting HCV and HBV. 
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N % n % of N OR p AOR p
All 1288 100.0 34 2.6 1.9 3.7
Age Group* 18-29 256 19.9 2 0.8 0.2 2.8 ref ref
30-49 511 39.7 17 3.3 2.1 5.3 4.1 1.0 17.1 0.056 4.1 1.0 17.2 0.056
50-69 375 29.1 9 2.4 1.3 4.5
70+ 146 11.3 6 4.1 1.9 8.7
Gender Female 474 36.8 10 2.1 1.1 3.8 ref
Male 814 63.2 24 2.9 2.0 4.3 1.4 0.7 3.0 0.367
Country of Birth** UK 168 13.0 1 0.6 0.0 3.3 ref
Pakistan 882 68.5 27 3.1 2.1 4.4 5.1 0.7 37.3 0.111
India 137 10.6 4 2.9 1.1 7.3
Other 101 7.8 2 2.0 0.5 6.9
Recruitment Setting Mosque 833 64.7 23 2.8 1.8 4.1 ref
Community Centre 455 35.3 11 2.4 1.4 4.3 0.9 0.4 1.8 0.713
Deprivation Quintile Least Deprived 150 11.6 6 4.0 1.8 8.5 ref
2 181 14.1 2 1.1 0.3 3.9 0.3 0.1 1.3 0.110
3 195 15.1 4 2.1 0.8 5.2 0.5 0.1 1.8 0.294
4 350 27.2 11 3.1 1.8 5.5 0.8 0.3 2.1 0.629
Most Deprived 292 22.7 7 2.4 1.2 4.9 0.6 0.2 1.8 0.350
Not Known 120 9.3 4 3.3 1.3 8.3 0.8 0.2 3.0 0.774
Member of family 
No 989 76.8 28 2.8 2.0 4.1 ref
infected with HCV Yes 183 14.2 5 2.7 1.2 6.2 1.0 0.4 2.5 0.941
Not Known 116 9.0 1 0.9 0.0 4.7 0.3 0.0 2.2 0.237
Diabetes No 1045 81.1 25 2.4 1.7 3.5 ref
Yes 221 17.2 8 3.6 1.8 7.0 1.5 0.7 3.4 0.302
Not Known 22 1.7 1 4.5 0.2 21.8 1.9 0.3 15.0 0.524
Travelled in south 
Asia (SA) No/Not Known 59 4.6 1 1.7 0.1 9.0 ref
(1 Not Known) Yes 1229 95.4 33 2.7 1.9 3.7 1.6 0.2 11.9 0.646
Surgery in SA No/Not Known 1144 88.8 24 2.1 1.4 3.1 ref
(14 Not Known) Yes 144 11.2 10 6.9 3.8 12.3 3.5 1.6 7.4 0.001
Medical/Dental 
Treatment in SA No/Not Known 831 64.5 15 1.8 1.1 3.0 ref
(15 Not Known) Yes 457 35.5 19 4.2 2.7 6.4 2.4 1.2 4.7 0.014
Injection in SA No 990 76.9 18 1.8 1.2 2.9 ref
Yes 219 17.0 11 5.0 2.8 8.8 2.9 1.3 6.1 0.007
Not Known 79 6.1 5 6.3 2.7 14.0 3.6 1.3 10.1 0.013
No/Not Known 687 53.3 10 1.5 0.8 2.7 ref ref
Surgery 144 11.2 10 6.9 3.8 12.3 4.2 1.9 9.8 <0.001 5.0 2.0 12.3 <0.001
Medical/Dental/ Injection 
but Not Surgery 457 35.5 14 3.1 1.8 5.1 2.1 1.0 4.4 0.041 2.2 1.0 5.0 0.063
Blood Transfer in SA No/Not Known 1174 91.1 30 2.6 1.8 3.6 ref
(30 Not Known) Yes 114 8.9 4 3.5 1.4 8.7 1.4 0.5 4.0 0.546
Street Barber in SA No/Not Known 753 58.5 18 2.4 1.5 3.7 ref
(17 Not Known) Yes 535 41.5 16 3.0 1.8 4.8 1.3 0.6 2.5 0.509
Tattoo/Piercing in SA No/Not Known 1004 78.0 25 2.5 1.7 3.7 ref
(16 Not Known) Yes 284 22.0 9 3.2 1.7 5.9 1.3 0.6 2.8 0.530
Vaccination in SA No 254 19.7 4 1.6 0.6 4.0 ref
Yes 879 68.2 28 3.2 2.2 4.6 2.1 0.7 5.9 0.181




Table 1: Factors associated with HCV antibody prevalence in people of South Asian origin surveyed in Greater Glasgow and Clyde NHS Board during 2009-2010.
95% CI
Total Prevalence of HCV Antibodies Univariate Analysis Multivariate Analysis
95 % CI 95 % CI
*   In the univariate and multivariate analysis those aged <30 years old are compared with those aged 30 years and over.
**  In the univariate analysis UK born is compared with non-UK born.
*** This variable combines three questions on surgery in south Asia (SA), medical/dental treatment in SA, and injection in SA.
Table(s)
Table 2: Factors associated with HCV antibody prevalence in people of South Asian origin who had a diagnostic HCV test in Greater Glasgow and Clyde NHS Board during 1993-2009.
N % n % of N OR p AOR p
All 6404 100.0% 597 9.3 8.6 10.1
Age at first test 18-29 1824 28.5% 105 5.8 4.8 6.9 ref ref
30-49 3110 48.6% 284 9.1 8.2 10.2 1.6 1.3 2.1 <0.001 1.6 1.3 2.0 <0.001
50-69 1066 16.6% 141 13.2 11.3 15.4 2.5 1.9 3.3 <0.001 2.4 1.8 3.1 <0.001
70+ 284 4.4% 33 11.6 8.4 15.9 2.2 1.4 3.3 <0.001 2.3 1.5 3.5 <0.001
Not Known 120 1.9% 34 28.3 21.0 37.0 6.5 4.2 10.1 <0.001 6.0 3.7 9.5 <0.001
Gender Female 2625 41.0% 238 9.1 8.0 10.2 ref ref
Male 3256 50.8% 297 9.1 8.2 10.2 1.0 0.8 1.2 0.942 1.0 0.8 1.2 0.950
Not Known 523 8.2% 62 11.9 9.4 14.9 1.3 1.0 1.8 0.048 1.3 0.9 1.7 0.112
Year of first test 1993-2000 903 14.1% 128 14.2 12.1 16.6 ref ref
2000-2004 1924 30.0% 192 10.0 8.7 11.4 0.7 0.5 0.9 0.001 0.7 0.6 1.0 0.022
2005-2009 3577 55.9% 277 7.7 6.9 8.7 0.5 0.4 0.6 <0.001 0.6 0.5 0.8 <0.001
Referral Source* GP 2790 43.6% 326 11.7 10.5 12.9 ref ref
Hospital 2055 32.1% 223 10.9 9.6 12.3 0.9 0.8 1.1 0.366 0.7 0.6 0.9 <0.001
Routine 1281 20.0% 26 2.0 1.4 3.0 0.2 0.1 0.2 <0.001 0.1 0.1 0.2 <0.001
Other 278 4.3% 22 7.9 5.3 11.7 0.6 0.4 1.0 0.061 0.7 0.4 1.0 0.078
*Referral Source "Routine" includes Fertility/Assissted Conception (428), Occupational Health (508) and Renal (345), while "Other" includes Antenatal Clinic(29), Family Planning (1), GUM Clinic(10), Counselling 
Clinic(100), Drug Service/Harm Reduction (7), Prison (5), Not Known (20) and Other Not Specified (106).
Univariate Analysis Multivariate Analysis
95 % CI 95 % CI 95 % CI
Total Prevalence of HCV Antibody
Table(s)
Estimated population of South Asians (aged 
18+ years) living in GGC during 2009: 
N=28,430 
Figure 1: Estimated prevalence of HCV antibodies (anti-HCV) among South Asians living in Greater Glasgow & Clyde (GGC) during 2009.  
Number who have had a diagnostic HCV antibody 
test in GGC during 1993-2009: 
N=5,900 (21%) 
Estimated number who have NOT had a diagnostic 
HCV antibody test in GGC during 1993-2009: 
N=22,530 (79%) 
Number who tested 
anti-HCV negative: 
N=5,350 (90.7%) 
Number who tested 
anti-HCV positive: 
N=550 (9.3%) 
Estimated number born in 
the UK: 
N=8,320 (37%) 
Estimated number born 














Estimated population of anti-HCV positive South 
Asians (aged 18+ years) living in GGC during 2009: 
N=870 (3.1% of 28,430) 
Figure(s)
